Why HPV Self-Sampling Is Critical to Cervical Cancer Elimination in 2026

As cervical cancer elimination efforts accelerate, attention is increasingly focused on how proven screening tools are implemented into routine care.

Cervical cancer is moving from a narrative of missed opportunities to one of tangible, scalable solutions. Yet, disparities in access to screening and care, particularly in low- and middle-income countries (LMICs), remain unacceptable. Validated HPV testing with self-collection, along with timely triage and treatment, is reshaping cervical cancer prevention by making screening more accessible and sensitive. For clinicians and program leaders, the question is no longer whether these tools work, but rather how to implement them to close persistent gaps in access.

This companion article to the January blog, “January Reflections: Why 2026 Must Be the Year We Accelerate Cervical Cancer Elimination,” examines self-sampled HPV testing through an implementation lens, with a focus on clinical workflows, referral pathways, and program design. It highlights practical considerations for deploying self-collection at scale and ensuring that women who screen positive are efficiently linked to appropriate care.

Clinical Advantages of Primary HPV Testing

HPV testing is now the most effective screening method for cervical cancer when paired with timely triage and treatment.2 This shift not only enhances sensitivity but also enables flexibility across delivery models, freeing up resources for follow-up and treatment. As countries strive to meet WHO’s 2030 elimination targets1, national guidelines increasingly recommend primary HPV testing as the preferred screening modality.3 Countries are beginning to scale HPV testing nationally to meet the WHO 90–70–90 targets that call for 70% of women to be screened and 90% of women with disease to be treated.1 HPV screening can help achieve these goals because it detects more high-grade precancers earlier, allowing for longer screening intervals thereby reducing burden on clinics.

HPV screening can be paired with self-sampling, which expands reach and offers benefits beyond clinician-collected samples, especially in LMICs.2,3 Evidence now shows that self-collected HPV tests, when processed with validated HPV assays, are more sensitive than clinician-collected cervical samples for detecting high-risk HPV.2,3 The accuracy and sensitivity of self-collected testing enable 3-year screening intervals, alleviating the burden on healthcare systems.4 Women consistently report enhanced privacy, autonomy, and convenience, as well as reduced embarrassment or discomfort associated with speculum examinations.1 This is particularly important for survivors of trauma or in settings with gender norms that restrict pelvic exams.

For LMICs, self-sampling not only offers flexibility and convenience but provides a pathway to equity. Programs piloting self-collection consistently report improved uptake among under-screened populations, including those in rural or marginalized populations. For providers, self-collection supports task-shifting to community health workers and enables screening beyond traditional facilities while preserving testing integrity. Reflecting these benefits, guideline updates now recommend self-collected vaginal samples tested with validated PCR-based assays.2,3

Operationalizing the Screening Cascade

Self-sampling is a powerful tool to reach underserved women, but it requires strong referral pathways, data systems, and patient tracking to ensure linkage to care.

Effective cervical cancer prevention and management goes beyond HPV screening; success depends on the full cascade:1,2,3

Test → Triage → Treatment → Follow-up

Breaks at any step, especially loss to follow-up after a positive result, undermine the population-level benefits of high-quality HPV testing programs.1,2 Self-sampling is a powerful “test” step, but it only translates into cancer reduction if robust implementation pathways exist for triage, treatment, and surveillance.2

Large implementation studies highlight that loss to follow-up most often occurs after positive tests, when women must navigate fragmented referral systems, transport costs, and treatment delays. To preserve the advantages of HPV testing and self-sampling, programs need robust triage and clear referral pathways that are easy for both providers and patients to understand. For health professionals, building robust programs that embed triage and clear referral pathways will be key to ensuring that underserved women complete the journey from screening to treatment.4

Delivery Models for Self-Collection in Low-Resource Settings

For public health teams, the greatest need is robust implementation science to make these tools work in their community, not new tools.4 The WHO and national bodies increasingly endorse HPV testing, including self-collected samples, within organized screening programs that emphasize simplified, feasible workflows.1,3 Implementation science evaluates the equity, feasibility, acceptability, and practicality of effective interventions. Thereby bridging screening with real-world practice and community needs.

Same-day screen-and-treat implementation models, using HPV testing and ablative therapy, eliminate the need for multiple visits and can dramatically reduce loss to follow-up in LMICs. Other promising strategies include mobile outreach clinics, integrating screening with HIV care or maternal health services, and community campaigns where self-collection is offered alongside other preventive interventions. For clinicians, engaging with implementation models may mean rethinking roles and shifting tasks to nurses or community health workers while focusing specialist capacity on managing complex disease and quality assurance. These approaches offer practical and adaptable solutions informed by community needs and can help reach underserved women who would otherwise remain untreated.5

Clinical and Programmatic Priorities for Scale-Up

Where do we go from here? To meet the WHO 90–70–90 targets by 2030, we need a commitment to equity and a renewed focus on reaching underserved communities.1
For healthcare professionals, three practical priorities stand out: First, adopt HPV-based screening everywhere and advocate for the inclusion of self-collection options consistent with guideline recommendations. Second, design precise triage workflows and follow-up for HPV-positive women to focus treatment on those at high risk.4 Third, remain engaged with emerging evidence on vaccine schedules, new HPV assays, and evolving guidelines so that local protocols keep pace with a rapidly changing global landscape. Together, these steps can help translate powerful tools into equitable cervical cancer prevention that reaches the women who need it most.1

References
  1. WHO. Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2020. Accessed: 12/10/2025. Available: https://iris.who.int/server/api/core/bitstreams/4e245e89-ddcc-488f-97c7-9de5e08524ef/content
  2. Wentzensen N, Baena A. Human papillomavirus self-collection: The long road from scientific evaluation to implementation in screening programs. CA Cancer J Clin. 2026;76(1):e70047. doi:10.3322/caac.70047
  3. Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;76(1):e70041. doi:10.3322/caac.70041
  4. Phillips SA, Denoël S, Wentzensen N, Arbyn M. Accuracy of HPV Self-Collection Compared with Clinician-Collected HPV Testing and Cytology: A Meta-analysis. Cancer Epidemiol Biomarkers Prev. 2025;34(9):1467-1471. doi:10.1158/1055-9965.EPI-25-0362
  5. Stefan DC, Dangou JM, Barango P, Mahamadou ID, Kapambwe S. The World Health Organization targets for cervical cancer control by 2030: a baseline assessment in six African countries-part I. Ecancermedicalscience. 2022;16:1453. doi:10.3332/ecancer.2022.1453

Tags